PDF(Pubmed)
Abstract：
UNASSIGNED: The guidelines for treating chronic spontaneous urticaria (CSU) recommend using the IgE-targeted biologic omalizumab in patients with antihistamine-refractory disease.
UNASSIGNED: Our aim was to present a bibliometric review of publications related to omalizumab and CSU over the past 2 decades.
UNASSIGNED: Relevant publications from 2003 to 2022 were extracted from the Science Citation Index-Expanded (SCI-EXPANDED) database in the Web of Science Core Collection database as of January 8, 2023. We utilized CiteSpace (version 6.1.R3), VOSviewer (version 1.6.18), and the R package (version 4.2.1) to analyze and visualize the data. The R package bibliometrix (version 4.2.1) was also used.
UNASSIGNED: Between 2003 and 2022, a total of 566 articles on omalizumab and CSU were published. Since 2014, there has been a rapid increase in publication output. According to the collaboration network, the most influential country, institute, and scholar were the United States, Charité Universitätsmedizin Berlin, and Marcus Maurer, respectively. The study identified the Journal of Allergy and Clinical Immunology: In Practice as the most productive journal and the Journal of Allergy and Clinical Immunology as the most cocited journal. The analysis of key words revealed the presence of high-frequency terms such as angioedema, IgE, treatment, anti-IgE, asthma, and atopic dermatitis. Moreover, recent studies in this area have concentrated mainly on biomarkers, dupilumab, and coronavirus 2019 (COVID-19).
UNASSIGNED: There has been a growing interest in the use of omalizumab in CSU in recent years. The current trending topics in this research are the identification of biomarkers and the development of new mAbs for the treatment of CSU.
UNASSIGNED: Our aim was to present a bibliometric review of publications related to omalizumab and CSU over the past 2 decades.
UNASSIGNED: Relevant publications from 2003 to 2022 were extracted from the Science Citation Index-Expanded (SCI-EXPANDED) database in the Web of Science Core Collection database as of January 8, 2023. We utilized CiteSpace (version 6.1.R3), VOSviewer (version 1.6.18), and the R package (version 4.2.1) to analyze and visualize the data. The R package bibliometrix (version 4.2.1) was also used.
UNASSIGNED: Between 2003 and 2022, a total of 566 articles on omalizumab and CSU were published. Since 2014, there has been a rapid increase in publication output. According to the collaboration network, the most influential country, institute, and scholar were the United States, Charité Universitätsmedizin Berlin, and Marcus Maurer, respectively. The study identified the Journal of Allergy and Clinical Immunology: In Practice as the most productive journal and the Journal of Allergy and Clinical Immunology as the most cocited journal. The analysis of key words revealed the presence of high-frequency terms such as angioedema, IgE, treatment, anti-IgE, asthma, and atopic dermatitis. Moreover, recent studies in this area have concentrated mainly on biomarkers, dupilumab, and coronavirus 2019 (COVID-19).
UNASSIGNED: There has been a growing interest in the use of omalizumab in CSU in recent years. The current trending topics in this research are the identification of biomarkers and the development of new mAbs for the treatment of CSU.
摘要：
■治疗慢性自发性荨麻疹（CSU）的指南建议在抗组胺难治性疾病患者中使用IgE靶向生物奥马珠单抗。
■我们的目的是对过去20年与奥马珠单抗和CSU相关的出版物进行文献计量学综述。
■2003年至2022年的相关出版物是从截至2023年1月8日的WebofScienceCoreCollection数据库中的科学引文索引扩展（SCI-EXPANDED）数据库中提取的。我们使用了CiteSpace（6.1版。R3),VOSviewer（版本1.6.18），和R包（4.2.1版）来分析和可视化数据。还使用了R软件包bibliometrix（4.2.1版）。
■在2003年至2022年之间，共发表了566篇关于奥马珠单抗和CSU的文章。自2014年以来，出版物产量快速增长。根据合作网络，最有影响力的国家,研究所,学者是美国，柏林查理特大学，和MarcusMaurer,分别。该研究确定了《过敏与临床免疫学杂志：在实践中》是最有成效的杂志，《过敏与临床免疫学杂志》是最受欢迎的杂志。对关键词的分析揭示了诸如血管性水肿等高频术语的存在，IgE,治疗,抗IgE,哮喘,和特应性皮炎。此外，最近在这一领域的研究主要集中在生物标志物上，dupilumab,和2019年冠状病毒（COVID-19）。
■近年来，在CSU中使用奥马珠单抗的兴趣与日俱增。本研究当前的趋势主题是识别生物标志物和开发新的单克隆抗体治疗CSU。
■我们的目的是对过去20年与奥马珠单抗和CSU相关的出版物进行文献计量学综述。
■2003年至2022年的相关出版物是从截至2023年1月8日的WebofScienceCoreCollection数据库中的科学引文索引扩展（SCI-EXPANDED）数据库中提取的。我们使用了CiteSpace（6.1版。R3),VOSviewer（版本1.6.18），和R包（4.2.1版）来分析和可视化数据。还使用了R软件包bibliometrix（4.2.1版）。
■在2003年至2022年之间，共发表了566篇关于奥马珠单抗和CSU的文章。自2014年以来，出版物产量快速增长。根据合作网络，最有影响力的国家,研究所,学者是美国，柏林查理特大学，和MarcusMaurer,分别。该研究确定了《过敏与临床免疫学杂志：在实践中》是最有成效的杂志，《过敏与临床免疫学杂志》是最受欢迎的杂志。对关键词的分析揭示了诸如血管性水肿等高频术语的存在，IgE,治疗,抗IgE,哮喘,和特应性皮炎。此外，最近在这一领域的研究主要集中在生物标志物上，dupilumab,和2019年冠状病毒（COVID-19）。
■近年来，在CSU中使用奥马珠单抗的兴趣与日俱增。本研究当前的趋势主题是识别生物标志物和开发新的单克隆抗体治疗CSU。
